Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2025-12-30 @ 8:23 AM
Study NCT ID:
NCT00395434
Status:
COMPLETED
Last Update Posted:
2011-10-31
First Post:
2006-11-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Sponsor:
Mateon Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced Solid Tumors | View |
| None | Advanced Solid Tumours | View |
| None | Advanced Solid Tumor | View |
| None | Advanced Solid Tumour | View |
| None | Advanced | View |
| None | Malignant | View |
| None | Solid | View |
| None | Tumors | View |
| None | Tumours | View |
| None | Tumor | View |
| None | Tumour | View |
| None | Cancer | View |
| None | Malignant Solid Tumors | View |
| None | Malignant Solid Tumours | View |
| None | Malignant Solid Tumor | View |
| None | Malignant Solid Tumour | View |
| None | Metastatic Cancer | View |
| None | Metastatic Disease | View |
| None | Advanced Cancer | View |
| None | Vascular Disrupting Agent | View |
| None | Anti-angiogenesis agent | View |
| None | Phase 1 | View |